Safety, Pharmacokinetics and Efficacy Study of MP-214 in Patients With Schizophrenia
Status:
Completed
Trial end date:
2009-09-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the safety, pharmacokinetics and efficacy of 3 fixed
doses of MP-214 orally administered once daily to patients with schizophrenia. MP-214 tablets
will be administered to patients starting at an initial dose, followed by up-titration to a
fixed dose (low, medium or high) for 14 days.